Try our mobile app

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Danaher Corporation designs, manufactures, and markets professional, medical, industrial and commercial products, and services in the sectors of test and measurement, environmental, life sciences, dental, and industrial technologies.
Website: danaher.com


  • Pretty weak financial results growth rate 4.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-4.9%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield 0.9% (LTM)
  • Share price is 23.4% higher than minimum and 23.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (31.4x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $115.0 mln (-0.072% of cap.)

Key Financials (Download financials)

Ticker: DHR
Share price, USD:  (-0.1%)215.58
year average price 207.30  


year start price 206.76 2025-02-07

min close price 174.64 2025-04-08

max close price 238.37 2026-01-10

current price 215.75 2026-02-06
Common stocks: 727 076 992

Dividend Yield:  0.6%
FCF Yield LTM: 0.9%
EV / LTM EBITDA: 31.4x
EV / EBITDA annualized: 25.3x
Last revenue growth (y/y):  +4.6%
Last growth of EBITDA (y/y):  +4.8%
Historical revenue growth:  +0.6%
Historical growth of EBITDA:  -10.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 156 743
Net Debt ($m): 13 810
EV (Enterprise Value): 170 553
EBITDA LTM ($m): 5 432
EV / LTM EBITDA: 31.4x
Price to Book: 3.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-30seekingalpha.com

Danaher Stock Plunge Does Not Represent A Good Entry Point

2026-01-28zacks.com

Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

2026-01-28zacks.com

Danaher (DHR) Beats Q4 Earnings and Revenue Estimates

2026-01-28reuters.com

Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

2026-01-23zacks.com

Insights Into Danaher (DHR) Q4: Wall Street Projections for Key Metrics

2026-01-23zacks.com

Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?

2026-01-21zacks.com

Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2026-01-13seekingalpha.com

Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13seekingalpha.com

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

2025-12-24prnewswire.com

HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data